Getinge recieves FDA premarket approval for the iCast™ covered stent system in the US

Error message

Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

GOTHENBURG, Sweden, March 24, 2023 /PRNewswire/ -- Getinge's iCast™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.

Metadata

Provider:

PR Newswire

Retrieved on:

Friday, March 24, 2023

Information

Tags:

Obesity, Diabetes, PAD, Moyamoya disease, Atherosclerosis, Polytetrafluoroethylene, Patient, Getinge, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Stent, Pharmaceutical industry

Geotags:

SWEDEN, UNITED STATES, US

Organisation:

GETINGE

Stock Symbol:

Summary

Key Points:

GOTHENBURG, Sweden, March 24, 2023 /PRNewswire/ -- Getinge's iCast™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.
"We are pleased that the iCast™ stent system is approved in the United States for use in iliac arteries to benefit an even greater number of patients", says Elin Frostehav, President Acute Care Therapies at Getinge.
Getinge will continue to ramp up capacity throughout the year in order to meet the demand."
The iCast covered stent system, which is sold outside the US under the brand name Advanta V12 covered stent, has been used by clinicians for 20 years and is the most clinically evaluated balloon expandable polytetrafluoroethylene (ePTFE)-covered stent in the world, with clinical data published in more than 550 articles.

Getinge recieves FDA premarket approval for the iCast™ covered stent system in the US

GOTHENBURG, Sweden, March 24, 2023 /PRNewswire/ -- Getinge's iCast^™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.

Iliac arterial occlusive disease is a type of peripheral arterial disease (PAD), a serious condition that only in the US affects 8 million persons,¹ in which atherosclerosis narrows and blocks peripheral arteries. As the world population ages and rates of diabetes and obesity rise, it is estimated that more people will be affected with iliac artery disease.

"We are pleased that the iCast™ stent system is approved in the United States for use in iliac arteries to benefit an even greater number of patients", says Elin Frostehav, President Acute Care Therapies at Getinge. "The global market for covered stents is growing at an annual rate of 5%. Getinge will continue to ramp up capacity throughout the year in order to meet the demand."

The iCast covered stent system, which is sold outside the US under the brand name Advanta V12 covered stent, has been used by clinicians for 20 years and is the most clinically evaluated balloon expandable polytetrafluoroethylene (ePTFE)-covered stent in the world, with clinical data published in more than 550 articles.

Media contact:

Anna Appelqvist, Corporate Communications
Phone: +46 (0)10 335 5906
Email: [email protected]

About Getinge

Getinge is a global provider of innovative solutions for operating rooms, intensive-care units, sterilization departments and for life science companies and institutions. Based on our first-hand experience and close partnerships with clinical experts, healthcare professionals and medtech specialists, we are improving the everyday life for people, today and tomorrow.

¹Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45(Suppl S):S5–S67

The following files are available for download:

https://mb.cision.com/Main/942/3740488/1940861.pdf	Getinge recieves FDA premarket approval for the iCastâ„¢ covered stent system in the US
https://news.cision.com/getinge/i/elin-1200x600,c3159934	Elin 1200x600
https://news.cision.com/getinge/i/icast-stent,c3159948	iCast stent

View original content:https://www.prnewswire.com/news-releases/getinge-recieves-fda-premarket-approval-for-the-icast-covered-stent-system-in-the-us-301781051.html

SOURCE Getinge